- The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2.
- Its other business is more steady, but also had a good quarter.
- Given the growth, the large margin expansion and profitability, and the additional HIFU treatment opportunities further away in time we think the shares are cheap.
EDAP Is At An Inflection Point
October 7th, 2019 · No Comments